Seeking Alpha
29 Jul 2026, 01:03 UTC · 7w ago
Verdict
Headline takes no side. We score ARGX +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The analyst upgraded argenx to a BUY rating with a price target of $1,050.
More positive than 92% of claims this week
VYVGART is experiencing robust commercial momentum through expanded indications, at-home administration, and a growing prescriber base.
So whatSustained growth of the primary revenue driver directly improves earnings forecasts and valuation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
The pipeline, specifically empasiprubart and autoimmune myositis, offers potential valuation upside.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The analyst upgraded the stock to BUY due to strong VYVGART growth, label expansion, and pipeline upside.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
3d ago
+13.5%
Price agrees with the score
$990.32 vs $872.23 close before publication (Jul 28) · not market-adjusted
ARGX chart →
